This HTML5 document contains 99 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q65353731
rdf:type
wikibase:Item
schema:description
clinical trial ensayu clínicu klinisch onderzoek клінічне випробування
rdfs:label
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
skos:prefLabel
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
schema:name
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
p:P1476
wds:Q65353731-95D91B8E-74C5-4BDC-9279-9CA6D0A4BA7F
wdt:P1476
TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) After Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum-doublet Chemotherapy
p:P582
wds:Q65353731-652AE75F-E9D3-40CE-A479-9EC3AAFEDD21
wdt:P582
2018-03-29T00:00:00Z
p:P31
wds:Q65353731-F9287E8B-F06D-44B7-B30B-77F507038EF2
wdt:P31
wd:Q30612
p:P580
wds:Q65353731-1993ABA7-FAFB-477F-9DC4-95D6DB591348
wdt:P580
2015-02-01T00:00:00Z
p:P17
wds:Q65353731-2EFF3B21-34DF-4B66-A50D-F0D69FF803F5 wds:Q65353731-6037E2FC-5975-4701-89FA-672E90444716 wds:Q65353731-5BD2F791-F024-4856-8E35-42B408AFA1F9 wds:Q65353731-1E211E8C-508A-45B8-9E60-97F3A27FABC3 wds:Q65353731-F6B65455-673F-47BD-95EB-BD67C7BB80DC wds:Q65353731-EF39262E-5746-42CA-8894-87426F4699B7 wds:Q65353731-F2B9F6E7-433F-4208-ADE5-ACF121C0183F wds:Q65353731-B81B8ED4-F1BB-4F3D-AED4-A0DE74E259D2 wds:Q65353731-A0D1463F-8AB6-4709-A974-833BD03D875C
wdt:P17
wd:Q183 wd:Q145 wd:Q55 wd:Q30 wd:Q29 wd:Q142 wd:Q38 wd:Q408 wd:Q865
p:P6153
wds:Q65353731-5D379427-7D3E-4F83-91C7-075BF9E8863D wds:Q65353731-5F00CC6F-D712-4271-B344-462AA30E9595 wds:Q65353731-6356F5FC-4F48-4518-A9C0-6ED8F5C377A5 wds:Q65353731-6401B270-147C-4D47-9592-F46EAF13E51E wds:Q65353731-64526892-835C-4D15-BE34-E94970936E20 wds:Q65353731-3EF3345E-F155-4324-A0BF-FE33F92715F5 wds:Q65353731-4A03AA2A-EFFC-4031-A45C-93E0A9E250D5 wds:Q65353731-51478F63-2A4D-466E-B980-443B130DB3EE wds:Q65353731-53A1A343-E974-4F28-B52B-3A1D07A3675D wds:Q65353731-5BC7F1E7-FB2C-4A1C-BA8C-BE4730ABA0A8 wds:Q65353731-0335A422-9C7A-4374-910D-4EC4A54AD017 wds:Q65353731-1554BC1F-7DD6-4409-955A-B6599C5FB24D wds:Q65353731-2B5E009A-6B99-44D0-8448-303F93450020 wds:Q65353731-FB04C06A-201A-4023-AF0E-A937267A4BC6 wds:Q65353731-B572D9FD-FC40-4ADC-96C6-0330AF3E2E4C wds:Q65353731-BB5180C0-937B-41E6-891D-A02300FBF2D3 wds:Q65353731-C30C2065-FBC9-4C34-B3EA-5734AD85D1D6 wds:Q65353731-C5F7EFD3-1EDA-48AC-9A0C-CA8E5ED4320E wds:Q65353731-CAFC03BE-55C9-4B24-9E89-47B0FC4A94D3 wds:Q65353731-D1E44DD8-6408-4C73-B59B-EE0D7C221FB2 wds:Q65353731-699F6200-711B-4A21-A94F-C3601F5B09F3 wds:Q65353731-79DE35C9-07D4-4BE8-BD2B-537FDFD65AC2 wds:Q65353731-93546117-482B-498E-B3CB-184CDEC0428B wds:Q65353731-994F1A91-7C57-434E-A63E-7638B51C7329
wdt:P6153
wd:Q1137652 wd:Q4803501 wd:Q20102153 wd:Q624119 wd:Q3886646 wd:Q7252431 wd:Q623851 wd:Q913126 wd:Q213439 wd:Q15901822 wd:Q4858714 wd:Q50035503 wd:Q7374599 wd:Q7989074 wd:Q7451677 wd:Q1418766 wd:Q174710 wd:Q170027 wd:Q7370121 wd:Q5110676 wd:Q309331 wd:Q56582915 wd:Q3145371 wd:Q706177
p:P4844
wds:Q65353731-E26944F4-FC74-4729-8181-528BA4057E52 wds:Q65353731-7003BE1C-1446-4704-8459-970145DDCBEA
wdt:P4844
wd:Q423762 wd:Q415220
p:P2899
wds:Q65353731-D413A8DB-3F4E-44FA-A507-38C4E190900B
wdt:P2899
18
p:P1132
wds:Q65353731-42540857-6E55-45B8-8669-C9DDB1D45CF4
wdt:P1132
149
p:P8363
wds:Q65353731-899B6D9B-1E4B-4E9A-AEEE-E1E9B177AD1A
wdt:P8363
wd:Q78089383
p:P3098
wds:Q65353731-636AABC3-F288-4313-A772-DD689A4986EB
wdt:P3098
NCT02322281
p:P6099
wds:Q65353731-4527CDB4-6264-4F97-9784-61EB9BBF9EF1
wdt:P6099
wd:Q42824827